newsfilter
← Latest News
FDA Press Releases·

FDA Approves First Drug Shown to Help Patients with Infantile-Onset Niemann-Pick Disease Type C Live Longer

  • The FDA approved Lembaz (adrabetadex) injection on November 17, 2026, as the first treatment shown to reduce the risk of death in patients with infantile-onset Niemann-Pick disease type C (NPC).
  • Lembaz is indicated for adult & pediatric patients weighing at least 7 kg (about 15 pounds) whose neurological symptoms began before age 6.
  • Clinical data from 36 patients showed a 55% reduction in the risk of death & a median survival time of 8.5 years for the treated group compared to 4.9 years in the control group.
  • The medication is administered as an intrathecal injection directly into the spinal canal every two weeks by a trained healthcare provider.
  • Common side effects include hearing problems, balance & coordination issues, fatigue, vomiting, back pain, headache, fever, diarrhea, nausea, & cough.
  • Lembaz carries a boxed warning for hearing impairment, including permanent hearing loss, requiring comprehensive hearing evaluations before & during treatment.
  • The approval was granted to Mandos, LLC, a subsidiary of Beren Therapeutics, PBC, following the drug's Breakthrough Therapy designation.